Una candidatura completa in un minuto
Curriculum e lettera di presentazione personalizzati, pronti da inviare.
DBV Technologies is seeking a skilled Medical Writer to support the development of clinical trial documents and regulatory submissions. The role focuses on scientific writing in accordance with regulatory guidelines, with experience in creating clinical study reports, protocols, Investigator’s Brochures, DSURs, and regulatory submissions.
The successful candidate will read and summarize efficacy and safety data in concise, regulatory-compliant language, work under tight deadlines, and coordinate
DBV Technologies is seeking a skilled and detail-oriented Medical Writer to support the development of clinical trial documents and regulatory submissions. This role focuses on scientific writing in accordance with regulatory guidelines. The ideal candidate has extensive writing experience developing clinical study reports, protocols, Investigator’s Brochures, DSURs, regulatory submissions (BLA/NDAs), and related documents.
DBV Technologies is seeking a skilled and detail-oriented Medical Writer to support the development of clinical trial documents and regulatory submissions. This role focuses on scientific writing in accordance with regulatory guidelines. The ideal candidate has extensive writing experience developing clinical study reports, protocols, Investigator’s Brochures, DSURs, regulatory submissions (BLA/NDAs), and related documents. The successful candidate will work efficiently under shortened deadlines, communicate proactively with stakeholders to ensure adherence to established timelines, and be able to read and summarize efficacy and safety data in succinct, regulatory-compliant language. Additional responsibilities may be assigned depending on project needs and organizational priorities.
Warren, New Jersey - minimum 3 days on site
$105-130k
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.
We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need.
This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin.
Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy.
Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.